Glaukos Corporation $GKOS Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL lessened its holdings in Glaukos Corporation (NYSE:GKOS) by 54.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,701 shares of the medical instruments supplier’s stock after selling 4,399 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Glaukos were worth $418,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GKOS. Wellington Management Group LLP increased its holdings in Glaukos by 10.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after purchasing an additional 336,266 shares during the period. Primecap Management Co. CA increased its holdings in Glaukos by 23.3% during the 3rd quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock worth $183,796,000 after purchasing an additional 425,790 shares during the period. State Street Corp increased its holdings in Glaukos by 5.3% during the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after purchasing an additional 105,972 shares during the period. Ameriprise Financial Inc. increased its holdings in Glaukos by 3.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after purchasing an additional 68,497 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in Glaukos by 38.5% during the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock worth $141,365,000 after purchasing an additional 481,620 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of GKOS opened at $120.95 on Friday. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $148.11. The firm’s fifty day simple moving average is $120.19 and its 200-day simple moving average is $113.34. The firm has a market capitalization of $7.10 billion, a price-to-earnings ratio of -36.88 and a beta of 0.94. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. During the same period last year, the business earned ($0.22) EPS. The company’s revenue was up 41.2% on a year-over-year basis. Equities analysts forecast that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Insider Activity

In related news, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director directly owned 35,528 shares of the company’s stock, valued at $5,000,921.28. This trade represents a 12.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 19,573 shares of Glaukos stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the sale, the chief operating officer owned 73,419 shares in the company, valued at $10,538,563.26. This represents a 21.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,930 shares of company stock valued at $6,321,363 over the last quarter. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

GKOS has been the topic of several recent research reports. Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Stifel Nicolaus set a $170.00 price target on Glaukos in a report on Thursday, April 30th. Wells Fargo & Company raised their price objective on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Citigroup raised their price objective on shares of Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $146.17.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Wall Street analyst commentary was still constructive overall, with BTIG reiterating a Buy rating and setting a $162 price target, while other firms also maintained bullish views. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Positive Sentiment: Zacks Research raised some near-term and longer-term earnings estimates for Glaukos, suggesting analysts still see improving profitability over time. Article: Glaukos Corporation analyst updates
• Neutral Sentiment: Recent quarterly results were stronger than expected, with Glaukos beating EPS and revenue estimates and reporting 41% year-over-year revenue growth, which helped fuel the earlier rally. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Neutral Sentiment: The stock’s recent rise also came after management lifted its 2026 sales outlook, leaving shares vulnerable to a short-term reset if momentum cooled. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Negative Sentiment: Recent insider-sale filings, including a CFO stock sale under a pre-arranged trading plan, added to near-term selling pressure and may have amplified concerns about insider sentiment. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.